Profile data is unavailable for this security.
About the company
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
- Revenue in USD (TTM)110.32m
- Net income in USD-70.69m
- Incorporated2014
- Employees130.00
- LocationArcellx Inc800 Bridge ParkwayREDWOOD CITY 94065United StatesUSA
- Phone+1 (240) 327-0603
- Fax+1 (302) 655-5049
- Websitehttps://www.arcellx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics Inc | 8.08m | -58.29m | 2.43bn | 64.00 | -- | 6.33 | -- | 301.03 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 2.49bn | 105.00 | -- | 32.06 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.59bn | 91.00 | -- | 5.84 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Neogen Corp | 929.24m | 1.57m | 2.59bn | 2.64k | 1,658.81 | 0.8234 | 21.98 | 2.79 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.40 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| Hims & Hers Health Inc | 872.00m | -23.55m | 2.63bn | 1.05k | -- | 7.61 | -- | 3.01 | -0.1131 | -0.1131 | 4.17 | 1.61 | 2.16 | 7.13 | 195.17 | 833,652.00 | -5.83 | -- | -7.02 | -- | 81.99 | -- | -2.70 | -- | 2.74 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Merus NV | 43.95m | -154.94m | 2.64bn | 172.00 | -- | 7.29 | -- | 60.00 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.69bn | 597.00 | -- | 6.22 | -- | 3.70 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.70bn | 50.00 | -- | 5.15 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 2.71bn | 525.00 | -- | 14.66 | -- | 14.91 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.74bn | 130.00 | -- | 5.53 | -- | 24.82 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 2.83bn | 497.00 | -- | 7.82 | -- | 11.34 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Azenta Inc | 641.02m | -17.37m | 2.87bn | 3.50k | -- | 1.17 | 41.09 | 4.48 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 2.88bn | 124.00 | -- | 4.04 | -- | 123.14 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.00bn | 517.00 | -- | 18.64 | -- | 7.52 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.02bn | 251.00 | -- | 3.26 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Data as of Apr 26 2024. Currency figures normalised to Arcellx Inc's reporting currency: US Dollar USD
48.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2023 | 4.54m | 8.61% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.10m | 7.77% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 3.66m | 6.93% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.73m | 5.17% |
| Suvretta Capital Management LLCas of 31 Dec 2023 | 2.44m | 4.61% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.97m | 3.72% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.77m | 3.36% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 1.70m | 3.22% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.53m | 2.89% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.24m | 2.35% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
